MedTrace Logo

Tumor Immunotherapy and Microbiome Analysis

NCT04579978 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-05-05

No results posted yet for this study

Summary

The composition of the gut microbiome has been associated with response and the development of toxicities on immune checkpoint inhibitors (ICIs) in multiple tumor types. The aim of this study is to examine the gut microbiome composition in patients undergoing standard of care treatment for advanced/unresectable and/or metastatic solid tumors with ICIs. Fecal samples and peripheral blood samples will be collected to further characterize the diversity of gut bacteria and to study potential mechanisms by which gut bacteria impact the immune response.

Conditions

  • Advanced Solid Tumor

Sponsors & Collaborators

  • Princess Margaret Hospital, Canada

    collaborator OTHER

  • University of Toronto

    collaborator OTHER

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Rossanna C. Pezo, MD/PhD · Sunnybrook Health Sciences Centre

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04579978 on ClinicalTrials.gov